Genome-Engineered iPSCs for Consistent CAR-T Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive cell therapies using patient- and donor-sourced cells face challenges in achieving consistent manufacturing, improving efficacy and persistence of lymphocytes, and addressing issues like cell exhaustion, tumor escape, and off-target toxicity, particularly in delivering therapies to all patients effectively.
Innovation Solution
The development of genome-engineered induced pluripotent stem cells (iPSCs) that are differentiated into non-pluripotent cells with specific genetic modifications, enabling targeted integration of exogenous polynucleotides for enhanced therapeutic properties such as improved persistence, cytotoxicity, and tumor penetration, using methods like CRISPR-mediated editing and chimeric antigen receptors (CARs) to promote desired effector cell functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If patient- and donor-sourced cells are used for adoptive cell therapy, then personalized treatment can be provided, but consistent manufacturing and delivery to all patients becomes difficult
Solution Approach 1:
The patent uses universal donor-derived iPSCs as a common platform that can be differentiated into various immune cell types (T cells, NK cells, CAR-T cells) to treat different cancers, replacing the need for personalized patient cell sourcing while maintaining manufacturing consistency
Solution Approach 2:
The patent creates standardized iPSC cell lines that serve as reproducible templates for generating therapeutic immune cells, allowing consistent copying and expansion of successful cell products across multiple patients without requiring personalized cell collection and processing
2Productivity
If primary lymphocytes are engineered directly, then rapid cell production is possible, but engineering reproducibility and uniformity deteriorates
Solution Approach 1:
The patent performs genetic engineering and validation on iPSCs before differentiation, ensuring that all cells receive the same genetic modifications in a controlled setting, which guarantees reproducibility and uniformity before the rapid expansion phase
Solution Approach 2:
The patent separates the engineering process from the expansion process by first engineering iPSCs in a controlled environment to establish uniformity, then differentiating and expanding the engineered cells, thereby decoupling reproducibility requirements from productivity requirements
3Productivity
If engineered effector cells are produced with high expansion capability, then cell quantity increases, but cell persistence and survival improve only marginally
Solution Approach 1:
The patent modifies multiple parameters simultaneously including genetic engineering of persistence genes (e.g., BCL2, survivin), optimization of culture conditions, and differentiation protocol adjustments to achieve both high expansion and long persistence, rather than optimizing for expansion alone
4Ease of manufacture
If genome engineering is performed on primary immune cells, then direct therapeutic cell production is achieved, but cell heterogeneity increases
Solution Approach 1:
The patent starts with homogeneous iPSC populations that can be genetically engineered uniformly, then differentiates them into immune cells through controlled protocols that maintain genetic and phenotypic homogeneity, avoiding the heterogeneity inherent in primary cell sources
Data Source
AI summary
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from the differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.